Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy

Ozdogan Algin, Merve; Öztuna, Funda; AYÇIÇEK, OLCAY; KÜÇÜK, Ahmet Oğuzhan; Pehlivanlar, Ayşegül; PEHLİVANLAR KÜÇÜK, Mehtap

doi:10.4274/haseki.galenos.2023.8862

Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy

Olcay AYÇİÇEK, (Karadeniz Teknik Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Ahmet Oğuzhan KÜÇÜK, (Karadeniz Teknik Üniversitesi Tıp Fakültesi Anesteziyoloji Anabilim Dalı Anesteziyoloji Yoğun Bakım Ünitesi, Trabzon, Türkiye)

Mehtap PEHLİVANLAR KÜÇÜK, (Karadeniz Teknik Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı Yoğun Bakım Ünitesi, Trabzon, Türkiye)

Merve OZDOGAN ALGİN, (Karadeniz Teknik Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Ayşegül PEHLİVANLAR, (Karadeniz Teknik Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Funda ÖZTUNA (Karadeniz Teknik Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Haseki Tıp Bülteni

5 1

Yıl: 2023 Cilt: 61 Sayı: 2 Sayfa Aralığı: 120 - 127 Metin Dili: İngilizce DOI: 10.4274/haseki.galenos.2023.8862 İndeks Tarihi: 06-05-2023

Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy

Öz:

Aim: Few studies have followed the effects of red blood cell (RBC) transfusion on patient outcomes throughout the disease course in lung cancer. The aim of our study was to evaluate the relationship between blood transfusion frequency and disease prognosis in lung cancer patients receiving chemotherapy, to review the complications experienced and our clinical practices. Methods: This study was conducted as an observational study between 01.07.2021 and 31.12.2021. Patients diagnosed with small- cell lung cancer were included in the study. Patient data were collected retrospectively. During the follow-up period, patients who received and did not receive blood transfusions were compared in terms of various clinical conditions. Results: A total of 405 patients were included. Blood transfusion was performed in 96 (23.7%) patients. While the rate of infection development was 68.8% in the transfused group, this rate was statistically significantly lower at 35.3% in the non-transfused group (p<0.001). The median progression rate was statistically significantly higher in the group with infection (p=0.001). It was determined that 21 (38.2%) patients who resulted in exitus were transfused with an average of 3.1±3.0 units, and an average of 2.81±2.24 units of blood was transfused to 75 (21.4%) of the 350 (86.4%) surviving patients. A statistically significant difference was found between whether blood transfusion was performed in surviving and non-survived patients (p=0.011). Conclusions: It was determined that RBC transfusions during the disease in patients with lung cancer patients who underwent chemotherapy may adversely affect survival and disease progression.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics,. CA Cancer J Clin 2019;69:7-34
2. Dicato M, Plawny L, Diederich M. Anemia in cancer. AnnOncol 2010;21( 7):67-72
3. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A et al. NCCN GuidelinesVersion 4.2021 Hematopoietic Growth Factors. J Natl Compr Canc Netw 2020;18(1):12-22
4. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, anduse of treatment guidelines and protocols. Am J Health Syst Pharm 2007;64(3):5-13. https://doi.org/10.2146/ajhp060601
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91(19):1616-1634
6. National Comprehensive Cancer Network. NCCN® clinical practice guidelines in oncology. Cancer-and chemotherapy- induced anemia version1.2018.
7. Kenar G, Koksoy EB, Urun Y, Utkan G. Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Support Care Cancer 2020;28(11):5235-5242. doi: 10.1007/s00520-020-05336-w.
8. U.S. Food and Drug Administration. Filgrastim aafi information 2018. Available at: https://www.access data.fda.gov/ drugsatfda_docs/label/2018/761080s000lbl.pdf
9. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9(10):1109-15.
10. Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines from the AABB: Red blood cell transfusion thresholds and storage. JAMA 2016;316:2025-2035
11. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40(15):2293-2306 https://doi. org/10.1016/j.ejca.
12. Tanaka A, Yoshino I, Makino S, Katsumata N, Takahashi K, Kuwano H et al. Questionnaire based survey on chemotherapy- induced anemia. Int J Clin Oncol 2014;19(3):411- 420. https://doi.org/10.1007/s10147-014-0677-3
13. Yong M, Riis AH, Fryzek JP, Moller BK, Johnsen SP. Predictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998–2003). Clinical Epidemiology 2011;3:91-99
14. Granfortuna J, Shoffner K, DePasquale SE, Badre S, Bohac C, Brandao C de O. Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study. Supportive Care in Cancer 2018;26:2031–2038
15. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of Red Blood Cell Transfusion on Anemia-Related Symptoms in Patients with Cancer. Journal Of Pallıatıve Medıcıne 2009;12(1). DOI: 10.1089/jpm.2008.0139
16. Watering LMG, Brand A, Houbiers JGA, Kranenbarg WM, Hermans J, Velde CJH. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg. 2001;88(2):267-72 DOI: 10.1046/j.1365-2168.2001.01674.x
17. Wang YL, Jiang B, Yin FF, Shi HQ, Xu XD, Zheng SS, Wu S, Hou SC. Perioperative Blood Transfusion Promotes Worse Outcomes of Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis. PLOSONE 2015 (16)| DOI:10.1371/journal.pone.0130122
18. Tai YH, Wu HL, Mandell MS, Lin SP, Tsou MY, Chang KY. The association of nonesmall cell lung cancer recurrence with allogenic blood transfusion after surgical resection: A propensity score analysis of 1,803 patients. European Journal of Cancer. 202;140:45-54
19. Cho S, Park J, Lee M, Lee D, Choi H, Gim G et al. Blood Transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta- analysis. Transl Lung CancerRes 2021;10(4):1700-1710. doi: 10.21037/tlcr-20-933
20. Sakin A, Sahin S, Yasa N, Demir C, Arici S, Geredeli C et al. Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Lung Cancer 2019;133:38-44. doi: 10.1016/j. lungcan.2019.05.007
21. Aoe K, Hiraki A, Maeda T, Katayama H, Fujiwara K, Tabata M et al. Serum hemoglobin leveldetermined at the first presentation is a poor prognostic indicator in patients with lung cancer. Intern Med2005;44:800-804
22. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database SystRev 2016;12;10(10):CD002042
23. Yazer MH, Podlosky L, Clarke. G, Nahirniak SM. Theeffect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44:10-15
24. Gantt CL. Red blood cells for cancer patients. Lancet 1982;2:363
25. Brand A. Immunological aspects of bloodtransfusions. Transpl Immunol 2002;10:183-90
26. Tiotiu A, Clement-Duchene C, Martinet Y. Prise en charge de l’anemiechimio-induite dans le cancer bronchique. Management of chemotherapy-inducedanemia in lung cancer. Revuedes Maladies Respiratoires 2015;32(8):809-821
27. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-1615

APA	AYÇIÇEK O, KÜÇÜK A, PEHLİVANLAR KÜÇÜK M, Ozdogan Algin M, Pehlivanlar A, Öztuna F (2023). Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. , 120 - 127. 10.4274/haseki.galenos.2023.8862
Chicago	AYÇIÇEK OLCAY,KÜÇÜK Ahmet Oğuzhan,PEHLİVANLAR KÜÇÜK Mehtap,Ozdogan Algin Merve,Pehlivanlar Ayşegül,Öztuna Funda Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. (2023): 120 - 127. 10.4274/haseki.galenos.2023.8862
MLA	AYÇIÇEK OLCAY,KÜÇÜK Ahmet Oğuzhan,PEHLİVANLAR KÜÇÜK Mehtap,Ozdogan Algin Merve,Pehlivanlar Ayşegül,Öztuna Funda Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. , 2023, ss.120 - 127. 10.4274/haseki.galenos.2023.8862
AMA	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. . 2023; 120 - 127. 10.4274/haseki.galenos.2023.8862
Vancouver	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. . 2023; 120 - 127. 10.4274/haseki.galenos.2023.8862
IEEE	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F "Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy." , ss.120 - 127, 2023. 10.4274/haseki.galenos.2023.8862
ISNAD	AYÇIÇEK, OLCAY vd. "Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy". (2023), 120-127. https://doi.org/10.4274/haseki.galenos.2023.8862

APA	AYÇIÇEK O, KÜÇÜK A, PEHLİVANLAR KÜÇÜK M, Ozdogan Algin M, Pehlivanlar A, Öztuna F (2023). Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. Haseki Tıp Bülteni, 61(2), 120 - 127. 10.4274/haseki.galenos.2023.8862
Chicago	AYÇIÇEK OLCAY,KÜÇÜK Ahmet Oğuzhan,PEHLİVANLAR KÜÇÜK Mehtap,Ozdogan Algin Merve,Pehlivanlar Ayşegül,Öztuna Funda Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. Haseki Tıp Bülteni 61, no.2 (2023): 120 - 127. 10.4274/haseki.galenos.2023.8862
MLA	AYÇIÇEK OLCAY,KÜÇÜK Ahmet Oğuzhan,PEHLİVANLAR KÜÇÜK Mehtap,Ozdogan Algin Merve,Pehlivanlar Ayşegül,Öztuna Funda Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. Haseki Tıp Bülteni, vol.61, no.2, 2023, ss.120 - 127. 10.4274/haseki.galenos.2023.8862
AMA	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. Haseki Tıp Bülteni. 2023; 61(2): 120 - 127. 10.4274/haseki.galenos.2023.8862
Vancouver	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy. Haseki Tıp Bülteni. 2023; 61(2): 120 - 127. 10.4274/haseki.galenos.2023.8862
IEEE	AYÇIÇEK O,KÜÇÜK A,PEHLİVANLAR KÜÇÜK M,Ozdogan Algin M,Pehlivanlar A,Öztuna F "Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy." Haseki Tıp Bülteni, 61, ss.120 - 127, 2023. 10.4274/haseki.galenos.2023.8862
ISNAD	AYÇIÇEK, OLCAY vd. "Prognostic Effects of Red Blood Cell Transfusion in Lung Cancer Patients Receiving Chemotherapy". Haseki Tıp Bülteni 61/2 (2023), 120-127. https://doi.org/10.4274/haseki.galenos.2023.8862